Purpose: We present a systematic screening for identifying associations between prescribed drugs and cancer risk using the high quality Danish nationwide health registries.
Methods: We identified all patients (cases) with incident cancer in Denmark during 2000-2012 (n=278,485) and matched each case to 10 controls. Complete prescription histories since 1995 were extracted. Applying a two-phased case-control approach, we first identified drug classes or single drugs associated with an increased or decreased risk of 99 different cancer types, and further evaluated potential associations by examining specificity and dose-response patterns.
Findings: 22,125 drug-cancer pairs underwent evaluation in the first phase. Of 4561 initial signals (i.e., drug-cancer associations), 3541 (78%) failed to meet requirements for dose-response patterns and specificity, leaving 1020 eligible signals. Of these, 510 signals involved the use of single drugs, and 33% (166 signals) and 67% (344 signals) suggested a reduced or an increased cancer risk, respectively. While a large proportion of the signals were attributable to the underlying conditions being treated, our algorithm successfully identified well-established associations, as well as several new signals that deserve further investigation.
Conclusion: Our results provide the basis for future targeted studies of single associations to capture novel carcinogenic or chemopreventive effects of prescription drugs.
Keywords: Cancer; Carcinogenicity; Chemoprevention; Denmark; Drug evaluation; Pharmacoepidemiology; Pharmacology; Screening.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.